

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of the groups n = 5

EQA round: AP1/21 - Antithrombotic Agents

Deadline: 02.04.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 1														
(108) Apixaban						32						32	28	88%
Samples and groups		[µg/L]												
Sample A1							CVP	65,3	4,6	32%	44,4	86,2	32	28 88%
(38) IL														10
(63) Sysmex														11
(94) Stago														7
Other														4
							3x 149, 1x 179							
Sample B1						32	CVP	272	11	25%	204	340	32	32 100%
(38) IL														10
(63) Sysmex														11
(94) Stago														7
Other														4
							3x 149, 1x 179							
Set 2														
(109) Dabigatran						33						33	31	94%
Samples and groups		[µg/L]												
Sample A2							CVP	51,5	3,6	32%	35	68	33	31 94%
(38) IL														10
(63) Sysmex														13
(94) Stago														6
Other														4
							3x 149, 1x 179							
Sample B2						33	CVP	215	11	25%	161	269	33	33 100%
(38) IL														10
(63) Sysmex														13
(94) Stago														6
Other														4
							3x 149, 1x 179							
Set 3														
(110) Rivaroxaban						38						38	36	95%
Samples and groups		[µg/L]												
Sample A3							CVP	72,9	3,0	25%	54,6	91,2	38	36 95%
(38) IL														12
(63) Sysmex														14
(94) Stago														7
Other														5
							4x 149, 1x 179							
Sample B3						38	CVP	311	9,7	25%	233	389	38	38 100%
(38) IL														12
(63) Sysmex														14
(94) Stago														7
Other														5
							4x 149, 1x 179							

st_kn_p

End of report

Printed: 09.04.2021